Category: ProUroCare Medical Inc

Shareholder Update

Current status update Please bookmark this page and check back periodically for the latest updates on news, events, and milestone achievements of interest to shareholders and investors. Presentation at the August 22, 2013 Annual Meeting of Shareholders Stan Myrum reviews our progress and outlines future plans (Presentation). July, 2013 Letter To Shareholders Included In The Proxy Mailing. In this Letter To Shareholders Stan Myrum outlines our progress over the last…

What is Elasticity Imaging?

Tissue Displacement Tissue displacement occurs anytime body tissue moves in response to pressure. As areas of abnormal tissue form within an organ, the tissue often becomes more dense and less elastic. When pressure is applied to the organ, abnormal tissue generally exhibits less displacement than normal tissue. This difference can be detected and measured.

Prostate Disease

Prostate cancer is the most common form of cancer and the second leading cause of cancer death in men over the age of 50. The National Cancer Institute estimates that approximately 241,000 men were diagnosed with prostate cancer and over 33,000 died from the disease in 2011. Screening. Currently, there are approximately 42 million men in the U.S. over the age of 50. For men in this age category, the…

The ProUroScan™ Prostate Imaging System

ProUroScan is an advanced medical imaging system that uses an array of sensors mounted on a rectal probe, a central processing unit and software and image construction algorithms to provide a real time color image of abnormalities in the prostate. The system provides an image or record of the pressures that are generated from palpation of the posterior surface of the prostate using a rectal probe. The system’s operation is…

Letter to Creditors and Shareholders December 17, 2014

Letter to Creditors and Shareholders December 17, 2014 Innovative Elasticity Imaging Technology Prostate cancer is the most common form of cancer and the second leading cause of cancer death in men. The current standard of care is to screen for the presence of prostate cancer beginning at age 50, normally as part of the patient’s annual physical exam.  Two tests are routinely performed: the digital rectal exam (“DRE”) and the…